Skip to main content

Evgen encouraged by trials progress

Evgen encouraged by trials progress

Drug discovery group Evgen Pharma said it is pleased with its progress on treatments under development. The business focuses on treatments for cancer, strokes and Multiple Sclerosis. The company also revealed encouraging data in recent preliminary reports from pre-clinical programmes in triple negative breast cancer, glioblastoma and ischaemic stroke.

Chief executive Stephen Franklin said: “We were delighted with the positive breast cancer interim data showing good tolerability and efficacy in this very difficult to treat patient population and are hopeful that these trends will be maintained in the final analysis…we are excited about the near-term prospects of the company.”

See the article in full at TheBusinessDesk.com

Contact Us

Online form

If you would like to speak to us about an investment opportunity or would like some information on how to invest with Seneca, please contact us and a member of the team will be pleased to help you.
  • Would you like to receive Seneca Partners Newsletter updates?

  • Would you like to receive Seneca Partners Onside Magazine?

  • Would you like to receive Seneca Partners Event Updates?

  • Before submitting this form, please confirm that you have read and agree with our website Terms & Conditions

  • This field is for validation purposes and should be left unchanged.
Visit Seneca Partners Website